Nurix Therapeutics Inc (NRIX)vsNovartis AG ADR (NVS)
NRIX
Nurix Therapeutics Inc
$27.26
+2.10%
HEALTHCARE · Cap: $2.67B
NVS
Novartis AG ADR
$156.08
-0.50%
HEALTHCARE · Cap: $286.29B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 7977% more annual revenue ($56.69B vs $701.94M). NRIX leads profitability with a 42.0% profit margin vs 22.5%. NRIX trades at a lower P/E of 10.1x. NRIX earns a higher WallStSmart Score of 65/100 (C+).
NRIX
Buy65
out of 100
Grade: C+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NRIX.
Margin of Safety
-67.2%
Fair Value
$93.84
Current Price
$156.08
$62.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 83.1%
Revenue surging 8426.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
ROE of -61.4% — below average capital efficiency
Distress zone — elevated risk
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NRIX
The strongest argument for NRIX centers on P/E Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 42.0% and operating margin at 83.1%. Revenue growth of 8426.0% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : NRIX
The primary concerns for NRIX are EPS Growth, Return on Equity, Altman Z-Score.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
NRIX profiles as a growth stock while NVS is a value play — different risk/reward profiles.
NRIX carries more volatility with a beta of 1.82 — expect wider price swings.
NRIX is growing revenue faster at 8426.0% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NRIX scores higher overall (65/100 vs 51/100), backed by strong 42.0% margins and 8426.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nurix Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?